Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP & Chief Technology Officer | February 24, 2025 | February 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vir Biotechnology, Inc.
Report date February 24, 2025 · Filed February 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,901 |
Reported balance
After 2025-02-24 transaction · row 1
1 source rowRow 1 · 2025-02-24 · Sale · Disposed 14,168 · Balance 117,901 F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2025 Filed Feb 25, 2025 15:43 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 14,168 | $9.45 | $133,935.77 |
DisclosureSEC source: 0001628280-25-007706 · wk-form4_1740516204.xml · nonDerivative · entry 1 HANLY ANN M. · CIK 0001854528 · EVP & Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,901 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:58 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,711 | $10.05 | $27,250.97 |
DisclosureSEC source: 0001628280-24-014468 · wk-form4_1712105892.xml · nonDerivative · entry 1 HANLY ANN M. · CIK 0001854528 · EVP & Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,069 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 19:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $10.11 | $0.00 |
DisclosureSEC source: 0001628280-24-006985 · wk-form4_1708994010.xml · derivative · entry 4 HANLY ANN M. · CIK 0001854528 · EVP & Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2034-02-21 F4 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2025, and the remainder vest in 36 equal monthly installments thereafter. F4 · ownership.direct: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2025, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 19:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 12,296 | $10.05 | $123,520.70 |
DisclosureSEC source: 0001628280-24-006985 · wk-form4_1708994010.xml · nonDerivative · entry 2 HANLY ANN M. · CIK 0001854528 · EVP & Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,780 F2 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 19:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-006985 · wk-form4_1708994010.xml · nonDerivative · entry 1 HANLY ANN M. · CIK 0001854528 · EVP & Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,076 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| March 30, 2023 Filed Mar 31, 2023 14:40 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,627 | $22.77 | $59,816.79 |
DisclosureSEC source: 0001209191-23-021853 · doc4.xml · nonDerivative · entry 1 HANLY ANN M. · CIK 0001854528 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,576 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 20:35 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,302 | $25.97 | $59,789.85 |
DisclosureSEC source: 0001209191-23-013006 · doc4.xml · nonDerivative · entry 2 HANLY ANN M. · CIK 0001854528 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,203 F3 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 20:35 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $27.01 | $0.00 |
DisclosureSEC source: 0001209191-23-013006 · doc4.xml · derivative · entry 4 HANLY ANN M. · CIK 0001854528 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2033-02-21 F5 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 20:35 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013006 · doc4.xml · nonDerivative · entry 1 HANLY ANN M. · CIK 0001854528 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,505 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. F2 · balance_after: Includes 532 shares of common stock acquired by the reporting person on May 31, 2022 pursuant to an employee stock purchase program. Read SEC document |
| March 30, 2022 Filed Mar 31, 2022 14:46 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,627 | $26.24 | $68,925.39 |
DisclosureSEC source: 0001209191-22-021728 · doc4.xml · nonDerivative · entry 1 HANLY ANN M. · CIK 0001854528 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,473 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 47,000 | $0.00 Strike: $29.48 | $0.00 |
DisclosureSEC source: 0001209191-22-012955 · doc4.xml · derivative · entry 3 HANLY ANN M. · CIK 0001854528 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2032-02-21 F3 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 53,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-012955 · doc4.xml · nonDerivative · entry 1 HANLY ANN M. · CIK 0001854528 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,100 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 20:20 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | PurchaseCommon Stock | 11.52 | $43.39 | $499.85 |
DisclosureSEC source: 0001209191-21-067380 · doc4.xml · nonDerivative · entry 1 HANLY ANN M. · CIK 0001854528 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11.52 F1 · ownership.nature: The purchase was effectuated by a minor through a trading account registered in the name of the reporting person's spouse. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 18:17 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $48.38 | $0.00 |
DisclosureSEC source: 0001209191-21-023838 · doc4.xml · derivative · entry 2 HANLY ANN M. · CIK 0001854528 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-03-28 F1 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on March 29, 2022, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 18:17 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023838 · doc4.xml · nonDerivative · entry 1 HANLY ANN M. · CIK 0001854528 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.